10h 7min, jan 25, 2026 y - Sartorius Albumedix (Nottingham) Key WP Review

Description:

11+1
Group materiality PM £985k
No shared comfort
Most recent acquisition in 2022
Full Group scope
Only sell 2 products called Prime or Non-Prime using Albumine (rm)

Journals testing
- accruals; cash in transit timing of payments to suppliers MLP
-royalty income only paid by Merck on self assessment
-FI/MA to thoroughly review & scrutinise

Revenue
-IC sales agreed to the Group IC system
-£2m royalty income disputed with Merck, not booked in
-Goods tested to dispatch and incoterms

FA
-AUC significant commissioning and trf to PPE £16m video obtained regarding use
-existence, depreciation, disposals testing

Inventories
-100% spares provision due to spares being consumables not resold MLP
- stocktake no issues
- only sell 2 products; made to order no wastage
- WIP is FG that hasn't passed QC approval; not too technical
-production cost absorption; not great they include tea/coffee etc. but is consistent to PYs

Added to timeline:

Date: